Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18530868 | 1.00 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2USP2LMNAMAPT | |
| SCHEMBL11973552 | 1.00 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2USP2LMNAMAPT | |
| SCHEMBL10012862 | 1.00 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2USP2LMNAMAPT | |
| SCHEMBL10709713 | 1.00 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2USP2LMNAMAPT | |
| SCHEMBL10011623 | 0.98 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2USP2LMNAMAPT | |
| SCHEMBL3247846 | 0.93 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2USP2LMNAMAPT | |
| SCHEMBL12716522 | 0.89 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2LMNAHPGDAPEX1 | |
| SCHEMBL2772386 | 0.87 | ALDH1A1 (0.76) | ALDH1A1SMN1; SMN2USP2LMNAMAPT | |
| SCHEMBL28887982 | 0.87 | ALDH1A1 (0.76) | ALDH1A1SMN1; SMN2USP2LMNAMAPT | |
| SCHEMBL11423947 | 0.87 | ALDH1A1 (0.76) | ALDH1A1SMN1; SMN2USP2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0290534-B1 | METAL SALT FUEL ADDITIVE STABILIZED WITH A THIADIAZOLE | The Lubrizol Corporation (US) | 1990-12-19 | — | — | EP | claimed |
| US-8753895-B2 | Surface modified metal nano-particle and use thereof | Postech Academy-Industries Foundation (KR) | 2014-06-17 | — | — | US | disclosed |
| US-20130273024-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130252274-A1 | Surface Modified Metal Nano-Particle and Use Thereof | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2013-09-26 | — | — | US | disclosed |
| US-8426358-B2 | Methods for treating atherosclerosis | AMGEN INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120168681-A1 | Surface Modified Metal Nano-Particle and Use Thereof | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2012-07-05 | — | — | US | disclosed |
| EP-2452683-A2 | Methods for treating atherosclerosis | Amgen Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2037928-B1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110206652-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC. (US) | 2011-08-25 | — | — | US | disclosed |
| EP-2037928-A2 | METHODS FOR TREATING ATHEROSCLEROSIS | Amgen Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080096900-A1 | Methods for treating atherosclerosis | AMGEN INC. (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2008002591-A2 | METHODS FOR TREATING ATHEROSCLEROSIS | AMGEN INC (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130273024-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | LCAT, PCSK9, CETP | ALDH1A1 2876/4885SMN1; SMN2 4625/4885USP2 2072/4885 |
| US-20080096900-A1 | Methods for treating atherosclerosis | LCAT, PCSK9, CETP | ALDH1A1 2876/4885SMN1; SMN2 4625/4885USP2 2072/4885 |
| US-20110206652-A1 | METHODS FOR TREATING ATHEROSCLEROSIS | LCAT, PCSK9, CETP | ALDH1A1 2876/4885SMN1; SMN2 4625/4885USP2 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.